Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to new research. The results of the year-long phase 3 clinical trial could revolutionize the future of diabetes care and help millions of people better manage their condition.